Kyinno Biotech Submits IPO Prospectus Highlighting EGFR/c-MET Dual-Target Efficacy Models for Overcoming TKI Resistance

Currently, the official website of the Center for Drug Evaluation (CDE) under the China National Medical Products Administration has announced that Johnson & Johnson's EGFR/MET bispecific antibody therapy, amivantamab injection, has been submitted for marketing approval and has been accepted. Previously, this therapy was approved in the United States for treating patients with non-small cell lung cancer (NSCLC) harboring EGFR exon 20 insertion mutations and was designated as a breakthrough therapy by the CDE for treating specific types of NSCLC. 

A large body of evidence suggests that the EGFR and c-Met signaling pathways exhibit partial compensatory effects and mediate cross-resistance to inhibitors of both pathways. Studies have found that abnormal activation of the c-Met/HGF signaling pathway induces acquired resistance to EGFR through HGF-mediated activation of the c-MET protein, which in turn activates downstream signaling pathways. Moreover, in lung cancer patients with acquired resistance to EGFR-TKIs, overexpression of HGF is often associated with the secondary T790M mutation of EGFR and c-MET amplification. Inhibition of the c-Met/HGF signaling pathway plays a significant role in overcoming EGFR-TKI resistance. 

Bispecific antibodies targeting EGFR/c-Met currently entering clinical trials include: Eli Lilly's LY3164530, EpimAb Biotherapeutics' EMB-101, Betta Pharmaceuticals' MCLA-129, and Hansoh Pharma's HS-20117.In addition, several EGFR/c-Met bispecific antibodies are in preclinical research. 

• HCC827-HGF Cell Validation Data is as follows:

• Dose-Response Matrix
  

• Synergy Score：

A Novel Bispecific Antibody Targeting EGFR and cMet Is Effective against EGFR Inhibitor–Resistant Lung Tumors. AACR.2016.

You can add WeChat (zhuisu2210) for consultation or contact us directly via the backend.